207_Combined course Presentations

New perspectives and future directions: Is there a role for “mAbs” and immunotherapy in SCLC ?

Potential “targets of treatment”:  Notch  FGFR  PI3KCA

 RET  FAK  CXCR4  PARP  PD-L1  VEGFR

Bunn Jr PA. et al. J Thor Oncol 2016;11